Efficacy of remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia.
- Author:
Zhi-Hai ZHENG
1
;
Jian-Da HU
;
Ting-Bo LIU
;
Xin-Ji CHEN
;
Jing LI
;
Bu-Yuan CHEN
;
Xiao-Yun ZHENG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; diagnosis; drug therapy; Male; Middle Aged; Prognosis; Retrospective Studies
- From: Chinese Journal of Hematology 2012;33(2):79-83
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the outcome of remission induction chemotherapy (IC) and prognostic in elderly patients with acute myeloid leukemia (AML).
METHODSThe clinical data of 156 AML patients older than 60 years in the Institute of Hematology, Union Hospital of Fujian Medical University from January 2003 to July 2010 were analyzed retrospectively. 104 patients received cytarabine-based regimens, including protocol DA,IA or CAG,while 52 patients received palliative treatment. The median survival time was compared between patients with and without IC. The prognostic factors were evaluated by using univariate and multivariate analyses.
RESULTS145 (93%) cases were followed-up. The median survival time was 316 days in 96 IC patients, compared with 37 days in 49 PT patients (P < 0.01). Not receiving induction chemotherapy,high-risk karyotype,hyperleukocytosis (> or = 100 x 10(9)/L), Charlson Comorbidity Index (CCI) > or = 2 were adverse prognostic factors of the survival time with univariate analysis, and all were independent poor factors affecting the survival time with multivariate analysis.
CONCLUSIONSIC can improve outcomes in elderly AML patients. The patients with hyperleukocytosis (> or = 100 x 10(9)/L) , high-risk karyotype, CCI > or = 2 and without receiving IC have poorer prognosis.
